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Abstract
Background: Compliance is a major issue in glaucoma care. It is usually poor in glaucomatous
patients, and may ultimately result in an acceleration of the disease progression and a risk of
blindness. Reasons for this poor compliance are complex and multifactorial, amongst which patient
satisfaction can be counted. The objective of this study was to develop a questionnaire to assess
patient satisfaction and compliance with eye-drop treatment.
Methods: A qualitative study was carried out to develop the questionnaire. An interview guide
was developed based on a literature review. Structured interviews of fifteen French and English
patients with primary open-angle glaucoma or intraocular hypertension were conducted by trained
interviewers of the native language of the interviewees. General concepts and subconcepts were
identified from the transcripts. The questionnaire was developed using the patient verbatim, and
submitted to six patients (French and English) for cognitive debriefing. Following patients'
comments, items were modified and restructured, and a pilot questionnaire was designed.
Results: Analysis of data from the interviews with patients and clinicians resulted in the elicitation
of concepts related to patient satisfaction and compliance with glaucomatous treatment. These
were further refined and used to generate a test questionnaire, which consisted of 46 items
grouped into 6 domains: patient characteristics, treatment characteristics, patient-clinician
relationship, patient experience with the disease and the treatment, interaction between the
patient and the treatment, and patient knowledge of the disease and the treatment.
Conclusion: The Eye-Drop Satisfaction Questionnaire (EDSQ) conceptual framework and items
were developed simultaneously in French and in English. This questionnaire could be used to
evaluate patient satisfaction and compliance with eye-drop treatment and would facilitate the
identification of patients at risk of being non-compliant prior to clinical trials or innovative device
tests. A psychometric study is under way to validate the questionnaire.
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Primary open-angle glaucoma (POAG) is the most com-
mon form of glaucoma. It is a chronic disease character-
ised by a progressive alteration of the optic nerve, leading
to visual impairment. Glaucoma is one of the three lead-
ing causes of visual impairment in developed countries
[1,2]. The prevalence of glaucoma is about 2% in people
over 40 years and increases with age [3-5]. Reported
increase in office visit rates is also directly associated with
ageing [6]. According to the World Health Organisation,
visual impairment was responsible for 2,286,000 disabil-
ity-adjusted life years in high-income countries in 2001
[7]. It has considerable impact on the economy because of
the non-medical costs associated with the incapacity and
dependency resulting from the disease, such as loss of
income, burden on carer, paid assistance and residential
adaptation [8]. Visual impairment also negatively affects
the Health-Related Quality of Life (HRQoL) of patients
[9,10], and constitutes a major cause of disability that
affects individuals, family and society, and is associated
with an increased risk of institutionalisation and death
[1,11-13].
In all prospective multi-centre trials, elevated intraocular
pressure (IOP) is a major risk factor of POAG, even
though up to 50% of reported glaucoma cases may have
"normal" or "average" IOP. Moreover, elevated IOP has
been observed in patients with ocular hypertension
(OHT), who may never develop glaucoma [14,15]. How-
ever, multiple randomised studies have established the
efficacy of IOP reduction in preventing glaucomatous pro-
gression [16-19]. Therefore, control of IOP remains the
main approach to glaucoma care, and several medical
strategies have been developed to improve care: medica-
tion, laser treatment and surgery. Treatment of glaucoma
or OHT with medications is a major factor in the control
of the progression of glaucoma, thus contributing to the
maintaining of patients' HRQoL [13,20-22]. Nevertheless,
non-compliance of glaucomatous patients with the pre-
scribed therapy is significant, and is a highly limiting fac-
tor in the management of glaucoma. Numerous barriers
to medication compliance exist, such as the lifelong-
nature of the treatment, situational/environmental factors
(e.g. travelling), medication regimen (e.g. difficulty in
self-administering eye-drop product; side effects), patient
factors (e.g. forgetfulness, wrong idea of their medical
condition) and provider factors (e.g. poor communica-
tion between physicians and patients) [20,23-26]. While
compliance with treatment is indeed multifactorial [27],
Woodside et al. have proposed and illustrated the rela-
tionship between satisfaction and behavioural intention
and attitude regarding health [28]. Specifically, glaucoma
patient satisfaction with his/her treatment has been
shown to be a key driver of compliance [29], and could
therefore be used as an endpoint to characterise patients
at risk of being non-compliant. This information could
help characterize the treatment features that need to be
improved by identifying the determinant of satisfaction.
To this end, we proposed to develop a questionnaire on
compliance and satisfaction with medications adminis-
tered as eye-drops (the Eye-Drop Satisfaction Question-
naire – EDSQ-) for glaucoma or IOP treatment. Recently,
the importance of the very first steps in the development
of a Patient-Reported Outcomes (PRO) questionnaire has
been pointed out, and includes the design of a thorough
and rigorous conceptual framework following patient ver-
batim [30]. This manuscript presents the development of
the conceptual framework based on patient and clinician
interviews, and the subsequent generation of the items
that constitute the EDSQ.
Methods
Concept development
Based on patient concerns about eye-drop treatment iden-
tified in the literature review, a project team consisting of
a health psychologist, two ophthalmologists and a group
of experts in the development of questionnaires first met
to design a list of concepts related to patients' expectations
and satisfaction with eye-drop treatment. This concept list
was used for the development of the clinician and patient
interview guides.
Clinician interviews
Five clinicians who had experience in the treatment of
patients suffering from glaucoma or ocular hypertension
were recruited. Interviews with the clinicians were con-
ducted either face-to-face (France; n = 3) or by phone
(United Kingdom; n = 2) by a health psychologist and a
trained reviewer, and lasted 30 to 45 minutes. Clinicians
received a financial incentive for their participation.
The clinician interview guide explored the following top-
ics: clinicians' perception of the disease (s), patient man-
agement, patients' expectations regarding their
management, ease of use and treatment constraint, com-
pliance with the treatment and patient education about
the disease and its treatment.
Patient interviews
At the time of their medical visit to their ophthalmologist,
patients were asked to participate in the study. They had
to be aged between 50 and 75 years; diagnosed with OHT;
and be treated with one or more ophthalmic drop(s).
Prior to the interview, all the patients included had to sign
an informed consent form. Fifteen voluntary patients (n =
9 in France and n = 6 in the United Kingdom) were
recruited, in private practices for French patients, and in
outpatient clinics for English ones. One-hour interviews
were conducted by a health psychologist (in France), andPage 2 of 9
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of the interviewees and interviewers, and were tape-
recorded. These took place at the same place patients were
recruited, (i.e. clinic or clinical practice), or at the patients'
home. Patients received a financial incentive for their par-
ticipation.
The patient interview guide explored the following points:
patients' perception of the disease, fear and worries linked
to the disease, patients' actual experience of the treatment,
ease of use and treatment constraint, efficacy and tolera-
bility of the treatment, information and communication
between clinicians and patients, compliance with the
treatment.
Analysis of clinician and patient interviews
The tapes of the patient and clinician interviews were first
transcribed. Then, the transcripts were analysed by the
health psychologist following the Interpretative Phenom-
enological Analysis approach [31], and used to amend
and complete the initial list of concepts. The concepts
within this second list were categorised into new global
concepts and detailed subconcepts to create a conceptual
framework.
Item generation
Based on the pooled data from French and English patient
verbatim extracted from the interview transcripts, the
items were simultaneously generated in French and Eng-
lish during a project team "item generation meeting" [32].
This process ensured that each item in the subsequent
questionnaire was relevant to both English and French
patients.
Following discussions between members of the project
team about the concepts and the choice of appropriate
response-scales and of the overall structure of the ques-
tionnaire, a first version was developed.
Evaluation of the content validity
Patient structured interviews were performed by native
speaking and trained interviewers to assess the question-
naire's clarity and ease of comprehension, cultural equiv-
alence and relevance of the questions. Participants were
different from those who took part in the concept devel-
opment phase, but were recruited using the same method
and criteria as those used for the recruitment of patients
for the first set of interviews.
Six face-to-face interviews (three per country) were per-
formed. Two patients were diagnosed with OHT and four
with POAG. Interviews were tape-recorded. During the
interviews, patients were asked questions on their under-
standing and the wording of the items. In addition, they
were asked to review each item of the questionnaire in
order to evaluate the clarity and ease of understanding on
first reading and the relevance of the items. Throughout
the interview, the interviewer prompted the patient to
ensure they gave as much feedback as possible.
Results and discussion
Interviews were performed between December 2005 and
January 2006.
Patients' characteristics
Socio-demographic and clinical characteristics of the
patients are summarised in Table 1. Of the fifteen patients
interviewed, seven were diagnosed with OHT and eight
with POAG. Eight patients were male and seven patients
were female. The mean age of the patients was 68 years (±
10 years); the majority of them were retired. French
patients had been diagnosed 16 years ago (± 9 years) on
average, and had been following a treatment for 15 years
on average. All patients were taking at least one type of
ophthalmic drop. One French patient was suffering from
tachycardia, and one from hypertension. Amongst Eng-
lish patients, one was suffering from prostate cancer, one
Table 1: Socio-demographic and clinical characteristics of the patients
Characteristics France (n = 9) United Kingdom (n = 6) Total (n = 15)
Pathology Ocular Hypertension 4 3 7
Primary Open-Angle Glaucoma 5 3 8
Time since diagnosis (years ± SD) 15 ± 9 NA* NA
Age Min-Max 50–82 59–81 50–82
Mean (years ± SD) 67 ± 12 70 ± 8 68 ± 10
Gender Male 6 2 8
Female 3 4 7
Living situation Alone 1 1 2
As a couple 7 5 12
Married 1 0 1
Working status Retired 6 6 12
Currently working 3 0 3
*, not availablePage 3 of 9
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had arthritis.
Concept elicitation
Therapeutic compliance is a major factor in the treatment
of glaucoma and prevention of blindness. However, com-
pliance remains poor in this disease area; patient satisfac-
tion has been identified as being one of the causes [28].
Based on these observations, we have developed a satis-
faction questionnaire on eye-drop treatment that will help
identify patients at risk of being non-compliant.
Qualitative analysis of pooled data from English and
French patients' and clinicians' interviews revealed six
major concepts. Some of these had already been
addressed and gathered from the preliminary literature
review, but interviews also allowed the elicitation of more
emotional aspects by placing the patient in the psycho-
sociological context of the disease. The conceptual frame-
work is presented in Figure 1. Concepts extracted from the
clinicians' and patients' interviews are presented in the
following sections, and are illustrated with selected cita-
tions from the interviews. Where French verbatim was
included, this was translated into English by a bilingual
English speaking native. This verbatim is annotated with
an asterisk in the text.
Patient characteristics
According to the clinicians' interviews, "non-compliant
(patients) are more often men*", a "retired 'old man' is
more compliant*", and "non-compliant (patients) are
more often young*". Patients reported physical difficulty
in self-administering drops ("the actual drop itself can be
difficult to put in"; "to put the drops in by myself would
be difficult*", "Yes, perhaps for people who are unsteady;
this is not my case*"), which could result in missing the
eye ("quite often it falls on the eye lid and trickles away so
I have to do it again"), and their discomfort in having to
put things in their eyes: "I hate instruments that get close
to the eyes*". Related to these remarks may be patients
mentioning that the presence of somebody (spouse, hus-
band or external help) would facilitate this step ("my
mother applied the drops to my father's eyes*"). Clini-
cians also expressed the discomfort and difficulty of the
drop instillation process ("they just seem to say that it's
hard to look in the mirror and hold one eye at the same
time as putting a drop in-so it's the coordination of the
whole thing – very rarely someone says that the bottle
itself is a problem, but that's rare"; "they find it hard to put
them in themselves"; "if someone was coming in regularly
to help them put the drop in they would be able to do it"),
and have observed that "plenty of those people will have
them put in by their wife or spouse". Factors related to
travel, whether professional or personal, constituted
another major reason of non-compliance with the treat-
ment. Some patients reported difficulties in having to
remember to take their bottle when they were away:
"always having my bottle with me", "even in another
country", "I have forgotten them when I have been away
from home". Clinicians also indicated that "professional
life makes the follow-up of the treatment difficult*". A
few patients explained that they were compliant with their
treatment because a person in their family or friends had
previously had glaucoma ("My dad having had glaucoma
that was badly treated. He was 80 years old and maybe
that at this age, you have other priorities. I knew I had to
be very careful and pay great attention to my condi-
tion*"). Finally, clinicians reported that non-compliance
could be explained by "the patients' attitude first of all,
and usually they are some other issues going on that make
them not bother to put the drops in".
Thus, patient characteristics including socio-demographic
criteria such as age and gender appear to have a direct
impact on eye-drop treatment compliance. Their level of
education also has an impact (data not reported). In par-
ticular, the marital status seems to be an important factor
in compliance; the presence of a partner, or any external
help, is a motivating factor for patients, either as a
reminder or as a direct participant who would administer
eye-drops. Previous glaucoma history in patients' entou-
rage may help in increasing their compliance, as the
patient could then be aware of the effects that might result
from an inappropriate treatment. Physical difficulties
including palsy, discomfort putting things in eyes, and
blink reflex when instilling the drops are a barrier regard-
ing the patients' compliance with eye-drop treatment.
Patient compliance is also related to the time they can
spend administering their drops during the day. Lastly,
travel or any modifications in patient habits often result in
forgetting to use their medication, and thus have a nega-
tive impact on compliance.
Conceptual framework for the Eye Drop Satisfaction Ques-ti naireFigure 1
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Daily frequency of the treatment was often given by
patients as having an impact on their compliance: "three
(drops) in the evening and two in the morning with a ten-
minute pause between the two drops", "the one (drop)
during the day, I might forget it", "the one in between I
might take it at dinner time and might take it at 4 o'clock".
Side effects and feelings of discomfort resulting from the
treatment were also reported by patients and clinicians: "It
stings. I don't want to take my drops tonight", "It stings
and it makes my eyes red. I'm going out tonight, I don't
want to have red eyes*", "It burned when I applied it. I
had puffy eyes, red eyes*".
Patients' compliance and/or satisfaction with the treat-
ment may be influenced by the characteristics of the treat-
ment itself, such as the frequency of daily intake, and the
time of intake. The amount and intensity of the treatment
side effects are major factors: the greater and more painful
the side effects, the less compliant the patients. Finally,
satisfaction is closely related to compliance; indeed, if the
patient is satisfied with the treatment in its overall fea-
tures, then he/she will be more compliant.
Patient-clinician relationship
Sharing information about the disease and the treatment
with their clinician and checking-up on the efficiency of
the treatment have been mentioned by most patients as
motivating factors for compliance and/or satisfaction:
"(About change in the visual field) without an ophthal-
mologist it is impossible to know about it on your own*",
"I know because every 6 months, I have an appointment
with my clinician and he measures my ocular tension.
And I noticed that from 17, I stabilized at 10 for each eye
and it's not changing anymore. For me, this is a good
result*"; A few patients said that they would be encour-
aged to continue their treatment if their physicians were
willing to train them how to administer their medication
and gave regular check-ups. The attention paid by the cli-
nician and positive feedback were also reported by
patients as motivating factors ("I consulted a specialist
who cheered me up, he told me that if the pathology is
treated early enough, it couldn't go badly*"; "I was diag-
nosed very early. It's lucky the ophthalmologist had a
good reaction, because some of them think that you are
making it up*").
A good relationship, including care, training, feedback
and regular check-ups with their clinician is essential to
patient satisfaction, and is likely to result in improved
compliance. This may be linked to the patients' difficulty
in evaluating the efficacy of their treatment themselves
because of the elusiveness of the disease. Only a clinician
(ophthalmologist) can inform patients about a change in
their medical condition (an improvement, deterioration
or stabilisation). A relationship based on trust and regular
check-ups of patients by their clinician is therefore neces-
sary to motivate patients to take their treatment.
Patient experience
The trouble the patients have remembering to take the
treatment, ("the constraint is thinking about it*"; "You get
in, you fall asleep, you wake up later and can't remember
if you have taken your drops") and the burden of admin-
istering drops in the eyes ("I can drive but it bothers me at
night, the car lights...that's why we stopped going out in
the evening*", "The only trouble is remembering to use
them") were just part of the list of constraints that may
result in not taking the medication. Patients expressed
their doubts about the effectiveness of the treatment
because of the absence of an immediate medical deterio-
ration in their condition if they don't take their drops ("I
didn't take all [my drops]) last week and feel fine"),
because of the absence of a fast and noticeable improve-
ment in their vision ("The difficulty is knowing if the
treatment is working*"; "sometimes because of poor effi-
cacy of the drops"). One patient reported his non-compli-
ance with any medication ("I don't actually like taking
medication, full stop"). Fear is very frequently reported as
being a factor contributing to the non-compliance of
patients. For clinicians, the association of glaucoma with
blindness was the most frequent fear found in glaucoma-
tous patients ("I think their first fear is 'am I going to go
blind or not?"). For the majority of the patients, the fear
of going blind was also the biggest fear linked to their
medical condition ("Yes, scared of going blind, more than
of being in a wheelchair*"; "I was worried at first, the fear
of going blind*"). Fear of surgery was also brought up.
Clinicians reported that they used these fears to incite
patients to be compliant with the eye-drop treatment
("Once they have gone through that, then you can tell
them about the medical treatments – we tell them that
most of the time the drops work"; "Fear of surgery is a real
fear; We use that to make sure they put the drops in").
Equally, having to take a treatment for life was another
factor that patients indicated: "At the beginning, it makes
me think, a lifelong treatment is never something pleas-
ant*".
Thus, patient experience with eye-drop treatment may
influence their compliance with it. Especially, compliance
is likely to be jeopardised if the treatment is perceived as
a constraint or if the patient has doubts about the effec-
tiveness of the treatment. Furthermore, fear of the disease
may also be a barrier to compliance: if the fear regarding
the illness and its consequences is too high, anxiety may
override the defensive mechanisms and lead to a denial of
the disease that could ultimately result in renunciation of
the treatment.Page 5 of 9
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Clinicians reported that patients have no or incorrect
knowledge about glaucoma and its symptoms ("A strong
non-compliance factor is the non-understanding of the
disease by the patient; there is no need to take treatment,
I don't feel symptoms*"; "Just preconceptions they have
about going blind basically and that is associated with the
word glaucoma"). Patients often indicated the lack of
information regarding their disease: "I have no informa-
tion*", "As with a lot of treatments, in medicine, they are
not very talkative about why you have to take a treatment,
what it does, the inconveniences, you don't know any of
these*". Patients confessed their attempts to self-diagnose
their disease: "I read in a book about glaucoma symptoms
about seeing a halo around the light and thought, I have
that symptom, so went to see the doctor", "Oh yes because
I always – they have a leaflet to tell you exactly what they
are doing for you and what the side effects might be, if you
have any, which was good, nothing to get upset about"),
and their need to be informed (talking about information:
"No, not much. I'd like to have more. But we read a lot of
things. My sister is also under treatment*".
Patients' knowledge about the disease treatment also
influences their compliance: patients will be satisfied if
they are regularly informed about their illness and in turn
will be more compliant with their treatment. To fully
understand the importance of being compliant with the
treatment, patients need to understand the reasons for
which they have to follow a treatment, especially when
the treatment has constraints. Consequently, clinicians
play a major role by supplying this information, which
underlines the need for a good relationship between
patients and clinicians.
Patient-treatment interaction
Patients mentioned forgetting to take the treatment or
deliberately interrupting it: "Sometimes I don't want to. I
told you it happened 3, 5, 10 times maximum in 3 years...
There is no reason... I think I did it consciously, so few
times in 3 years; it's neutral (without consequences). ...
Because I don't want to! I have children, and when they
were at school, I always told them – during the school year
you can take 2 mornings off no more...I do the same with
[name of the product]*". Other patients said they have
developed routines and organisational means to help
them remember to take their treatment: "When I get up in
the morning I usually have a wash and come back into the
kitchen and put one drop in my right eye"; "Well, I keep
the bottle on the bedside table so that usually it reminds
me"; "You just get into the routine – twice a day and it's
no big deal". But often, patients related these routines to
a necessity, and as such defined them as an obligation:
("But I have to admit that drops every evenings, it's a con-
straint*"). The repetitive aspect of the treatment could
also help the patient to accept the treatment, as reported
by a patient: "No, it's not restrictive because one drop in
each eye once a day before going to bed, it's a reflex, it's a
habit and it only takes 8 seconds*". The inconvenience of
the application device was raised as a problem for cor-
rectly measuring out the drops ("the bottles are not too
bad. It's a mass-produced drug and with some of them,
you have to be careful because there are at least 2 to 3
drops that come out*"). Its inconvenience was also noted
because of the difficulties in using it for elderly people
(talking about elderly people: "The bottles are very small
and so, when they press them they don't have the same
flexibility that we have in their fingers, and also, to have
to lean back your head can result in dizziness, they may
fall. That elderly people are non-compliant with these
kinds of treatments doesn't surprise me*"), or because of
their difficulty in administering the drops by themselves:
"I was doing it myself, but watching the mirror is not very
handy and I was missing my eyes. However, for some
other patients, "the bottle is not too badly designed*".
Interaction between patients and treatment is another fac-
tor to consider in patients' treatment compliance. On the
one hand, routines may help the patient to be compliant,
but on the other hand, these same routines might be per-
ceived as a constraint. Non-compliance might thus be a
way for patients to re-appropriate their life and to cope
with the anxiety and fear they associate with their disease.
The convenience of the application device and its ease of
use are an other major factor in satisfaction and/or com-
pliance with the treatment.
Item generation
Based on the conceptual framework and the verbatim of
the French and English patients' pooled-responses, a pilot
questionnaire was developed simultaneously in French
and in English. The questionnaire contained 56 items
assessing the following six concepts: a/Patient characteris-
tics, (18 items), b/Treatment characteristics (6 items), c/
Patient-clinician relationship (12 items), d/Patient treat-
ment experience (8 items), e/Patient-treatment interac-
tion (8 items), and f/Patient compliance (4 items). The
interviewees answered using to a 5-point Likert scale rang-
ing from "not at all" to "extremely" or from "never" to
"always".
Evaluation of the content validity
Cognitive debriefing was performed by interviewing six
patients with glaucoma (n = 4) or OHT (n = 2), in France
and in England. Overall, the majority of the items were
well understood and accepted by patients who made few
remarks regarding their difficulty in understanding and
completing the questionnaire. Twelve items were deleted
as they were not relevant or were redundant, and twelve
questions had to be reworded or slightly modified inPage 6 of 9
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General concepts Subconcepts Item contents
Patient characteristics Gender Patient sex
Age Patient age
Marital status Patient alone or in couple
Level of education Patient level of education
Professional activities Professional status
Number of working hours
Daytime availability Free time during the day to take drops
Travel (Professional/Personal) Frequency of night spent away from home
Frequency of long journeys
Ease of prescription renewal when away
Family environment Self-administering or external help
Previous experience with IOP or POAG in family or friends
Physical difficulties Physical difficulties such as shaking, arthritis...
Apprehension Discomfort
Worries putting things in eyes
Blink reflex
Treatment characteristics Intake frequency Number of times a day the drops are taken
Time of the intake Time of the day the treatment is taken
Multiplicity of treatment Number of different ophthalmic drops
Side-effects Presence of side-effects
Patient-clinician relationship Visit frequency to the clinician Number of visits per year
Satisfaction with visit frequency Satisfaction with the delay between two visits
Training Training in drop instillation
Clinician care Satisfaction about clinician care
Feedback and motivation Relation between feedback and motivation
Follow-up and motivation Relation between clinician follow-up and motivation
Patient experience Treatment as a burden Burden of the treatment
Fear regarding the disease Fear of the disease evolution
Diificulty in taking drops Satisfaction about the administration route
Thinking constantly about the disease Frequency of thinking about disease consequences
Feeling about lifelong treatment Perception as a constraint
Confidence in the treatment Confidence in the effectiveness of the treatment
Forgetting the treatment Frequency treatment is forgotten
Patient-treatment interaction Administration route Ease of medication use
Convenience of the delivery system in bottle opening
Convenience of the delivery system in drop dosing
Convenience of the delivery system in checking quantity of drops 
left in bottle
Storage of eye drops in good conditions
Routine Set up of routine for remembering to take drops
Daytime intake
Break in the treatment Voluntary treatment break
Self-assessment compliance Compliance with treatment over a given period
Patient knowledge Information received on disease and treatment Satisfaction about the quantity of information given on the 
treatment
Satisfaction about the quantity of information given on the disease
Frequency of information given by clinician to patient about eye-
pressure level
Frequency of information given by clinician to patient about visual 
field
order to make them clearer for the patients. Following
experts' comments, the order of the items was also modi-
fied in order to facilitate the completion of the question-
naire. The definition of the concepts was also refined and
restructured. These concepts and the associated subcon-
cepts are presented in Table 2.
The resulting EDSQ questionnaire, available in French
and English, contains 46 items, assessing 6 domains: 1/
Patient characteristics (16 items, including items on age,
gender, family and working status, travel, physical diffi-
culties and apprehension), 2/Treatment characteristics (4
items, including items on frequency and time of intake,Page 7 of 9
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nician relationship (6 items, including items on frequency
of visits, satisfaction with frequency of visits, training, sat-
isfaction with clinician care and impact of good feedback
and follow-up), 4/Patient experience (7 items, including
items on perceived constraints of the treatment, fear of the
disease, confidence in the treatment, forgetting the treat-
ment, difficulty in taking drops and thinking constantly
about the disease), 5/Patient-treatment interaction (9
items, including items on the ease and convenience of the
administration route, set up of routine, break in the treat-
ment, and self-assessment of compliance), and 6/Patient
knowledge (4 items related to the information received by
the patient on the disease and the treatment). For ease and
clarity, the questionnaire was divided into two distinct
parts, the first part dealing with socio-demographic items,
and the second with disease-related questions. Respond-
ents answered each item using either a dichotomous scale
(Yes/No) or a 5-point Likert type scale ranging from "not
at all" to "extremely" or from "never" to "always".
Conclusion
A conceptual framework and items were generated accord-
ing to the Guidance for Industry document published by
the Food and Drug Administration [30], and resulted in
the development of the EDSQ. To our knowledge, there is
no article describing the very first steps of the develop-
ment of a questionnaire on glaucoma eye-drop treatment
compliance and satisfaction. In this manuscript, the elab-
oration of a conceptual framework and the item genera-
tion based on a qualitative study of interviews with
glaucomatous patients are presented. The concepts and
subconcepts established herein support previous quanti-
tative studies that have provided evidence that patient sat-
isfaction may be related to compliance, perceived
effectiveness of treatment, side effects, ease and conven-
ience of use, acceptance of illness, and knowledge of glau-
coma [29,33,34]. Two limitations to the present work
should be noted; one may reside in the absence of satura-
tion as interview methodology [30,31,35]. However, the
conceptual framework that was elaborated from the pre-
liminary literature review and subsequent patients' and
clinicians' interviews appeared consistent and solid; this
framework was further confirmed with cognitive debrief-
ing. One should add that recent work has found that sat-
uration occurs within the first twelve interviews [36]. The
other limit might consist in the bias that could have been
introduced when translating French verbatim into English
before analysis. This may have resulted in the loss or mis-
interpretation of some information, although such issues
were not highlighted during cognitive debriefing. Further
psychometric validation is required to confirm the items.
This questionnaire will be useful to evaluate satisfaction
and compliance for patients receiving eye-drop treatment
for ocular hypertension and glaucoma, thus facilitating
the identification of patients at risk of being non-compli-
ant, and ultimately help to select the best patient candi-
dates for eye-drop treatment. In the current economic
climate, such a tool will render decision-making easier for
pharmaceutical industries that will want to test innovative
devices and newly developed treatments. A psychometric
validation of the EDSQ questionnaire is under way to
examine its psychometric properties; in addition, the
questionnaire is being currently translated and linguisti-
cally validated in Dutch, Spanish and Italian, which will
widen its use to international studies.
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